Influence of body mass index and albumin on perioperative morbidity and clinical outcomes in resected pancreatic adenocarcinoma

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Hendifar, Andrew ^a   Osipov, Arsen ^a   Khanuja, Jasleen ^a   Nissen, Nicholas ^a   Naziri, Jason ^a   Yang, Wensha ^a   Li, Quanlin ^a   Tuli, Richard ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SERUM ALBUMIN;

ADENOCARCINOMA; ADULT; AGED; BLOOD; BODY MASS; DISEASE FREE SURVIVAL; FEMALE; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; OBESITY; PANCREATIC NEOPLASMS; PATHOPHYSIOLOGY; RISK FACTOR; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; BODY MASS INDEX; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; OBESITY; PANCREATIC NEOPLASMS; RISK FACTORS; SERUM ALBUMIN; TREATMENT OUTCOME;

EID: 84993973370     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0152172     Document Type: Article

References (28)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64(1):9–29. doi: 10. 3322/caac.21208 PMID: 24399786.
2. Ariyama J, Suyama M, Satoh K, Sai J. Imaging of small pancreatic ductal adenocarcinoma. Pancreas. 1998; 16(3):396–401. PMID: 9548685.
3. Carpelan-Holmstrom M, Nordling S, Pukkala E, Sankila R, Luttges J, Kloppel G, et al. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut. 2005; 54(3):385–7. doi: 10.1136/gut.2004.047191 PMID: 15710987; PubMed Central PMCID: PMC1774412.
4. Schenk M, Schwartz AG, O'Neal E, Kinnard M, Greenson JK, Fryzek JP, et al. Familial risk of pancreatic cancer. J Natl Cancer Inst. 2001; 93(8):640–4. PMID: 11309441.
5. Silverman DT, Schiffman M, Everhart J, Goldstein A, Lillemoe KD, Swanson GM, et al. Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer. 1999; 80(11):1830–7. doi: 10.1038/sj.bjc.6690607 PMID: 10468306; PubMed Central PMCID: PMC2363127.
6. Batabyal P, Vander Hoorn S, Christophi C, Nikfarjam M. Association of diabetes mellitus and pancreatic adenocarcinoma: a meta-analysis of 88 studies. Ann Surg Oncol. 2014; 21(7):2453–62. doi: 10. 1245/s10434-014-3625-6 PMID: 24609291.
7. Stolzenberg-Solomon RZ, Graubard BI, Chari S, Limburg P, Taylor PR, Virtamo J, et al. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. Jama. 2005; 294(22):2872–8. doi: 10. 1001/jama.294.22.2872 PMID: 16352795.
8. Michaud DS, Giovannucci E, Willett WC, Colditz GA, Stampfer MJ, Fuchs CS. Physical activity, obesity, height, and the risk of pancreatic cancer. Jama. 2001; 286(8):921–9. PMID: 11509056
9. Coughlin SS, Calle EE, Patel AV, Thun MJ. Predictors of pancreatic cancer mortality among a large cohort of United States adults. Cancer causes & control: CCC. 2000; 11(10):915–23. PMID: 11142526.
10. Arslan AA, Helzlsouer KJ, Kooperberg C, Shu XO, Steplowski E, Bueno-de-Mesquita HB, et al. Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Archives of internal medicine. 2010; 170(9):791–802. doi: 10. 1001/archinternmed.2010.63 PMID: 20458087; PubMed Central PMCID: PMC2920035.
11. Larsson SC, Orsini N, Wolk A. Body mass index and pancreatic cancer risk: A meta-analysis of prospective studies. Int J Cancer. 2007; 120(9):1993–8. doi: 10.1002/ijc.22535 PMID: 17266034.
12. Aune D, Greenwood DC, Chan DS, Vieira R, Vieira AR, Navarro Rosenblatt DA, et al. Body mass index, abdominal fatness and pancreatic cancer risk: a systematic review and non-linear dose-response meta-analysis of prospective studies. Ann Oncol. 2012; 23(4):843–52. doi: 10.1093/annonc/ mdr398 PMID: 21890910.
13. Luo J, Margolis KL, Adami HO, LaCroix A, Ye W, Women's Health Initiative I. Obesity and risk of pancreatic cancer among postmenopausal women: the Women's Health Initiative (United States). Br J Cancer. 2008; 99(3):527–31. doi: 10.1038/sj.bjc.6604487 PMID: 18628761; PubMed Central PMCID: PMC2527801.
14. Li D, Morris JS, Liu J, Hassan MM, Day RS, Bondy ML, et al. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. Jama. 2009; 301(24):2553–62. doi: 10.1001/jama. 2009.886 PMID: 19549972; PubMed Central PMCID: PMC2760963.
15. Yuan C, Bao Y, Wu C, Kraft P, Ogino S, Ng K, et al. Prediagnostic body mass index and pancreatic cancer survival. J Clin Oncol. 2013; 31(33):4229–34. doi: 10.1200/JCO.2013.51.7532 PMID: 24145341; PubMed Central PMCID: PMC3821012.
16. Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, et al. Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab. Cancer. 2014; 120(12):1780–6. doi: 10.1002/cncr.28648 PMID: 24633933; PubMed Central PMCID: PMC4265390.
17. Gibbs J, Cull W, Henderson W, Daley J, Hur K, Khuri SF. Preoperative serum albumin level as a predictor of operative mortality and morbidity: results from the National VA Surgical Risk Study. Archives of surgery. 1999; 134(1):36–42. PMID: 9927128.
18. Bachmann J, Ketterer K, Marsch C, Fechtner K, Krakowski-Roosen H, Buchler MW, et al. Pancreatic cancer related cachexia: influence on metabolism and correlation to weight loss and pulmonary function. BMC cancer. 2009; 9:255. doi: 10.1186/1471-2407-9-255 PMID: 19635171; PubMed Central PMCID: PMC2741486.
19. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011; 12(5):489–95. doi: 10.1016/ S1470-2045(10)70218-7 PMID: 21296615.
20. Tan CR, Yaffee PM, Jamil LH, Lo SK, Nissen N, Pandol SJ, et al. Pancreatic cancer cachexia: a review of mechanisms and therapeutics. Front Physiol. 2014; 5:88. doi: 10.3389/fphys.2014.00088 PMID: 24624094; PubMed Central PMCID: PMC3939686.
21. Hendifar AE, Rose-tan C, Yaffee P, Osipov A, Tuli R, Jeon C, editors. Evaluating outcomes of pancreatic cancer patients with cacehxia. 2014 ASCO Annual Meeting; 2014; Chicago, Illinois.
22. Prado CM, Baracos VE, McCarger LJ, Reiman T, Mourtzakis M, Tonkin K, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progresion in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009; 15(8):2920–6. doi: 10.1158/1078-0432.CCR-08-2242 PMID: 19351764
23. Joglekar S, Asghar A, Mott SL, Johnson BE, Button AM, Clark E, et al. Sarcopenia is an independent predictor of complications following pancreatectomy for adenocarcinoma. Journal of surgical oncology. 2015; 111(6):771–5. doi: 10.1002/jso.23862 PMID: 25556324; PubMed Central PMCID: PMC4406850.
24. Peng P, Hyder O, Firoozmand A, Kneuertz P, Schulick RD, Huang D, et al. Impact of sarcopenia on outcomes following resection of pancreatic adenocarcinoma. Journal of gastrointestinal surgery: official journal of the Society for Surgery of the Alimentary Tract. 2012; 16(8):1478–86. doi: 10.1007/s11605-012-1923-5 PMID: 22692586; PubMed Central PMCID: PMC3578313.
25. Amini N, Spolverato G, Gupta R, Margonis GA, Kim Y, Wagner D, et al. Impact of total psoas volume on short- and long-term outcomes in patients undergoing curative resection for pancreatic adenocarcinoma: a new tool to assess sarcopenia. 2015; 19(9):1593–602. PMID: 25925237.
26. Verbeke CS. Resection margins in pancreatic cancer. Pathologe. 2013; 34 Suppl 2:241–7. PMID: 24196622. doi: 10.1007/s00292-013-1799-5
27. Campbell F, Smith RA, Whelan P, Sutton R, Raraty M, Neoptolemos JP, et al. Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin. Histopathology. 2009; 55:277–83. PMID: 19723142. doi: 10.1111/j.1365-2559.2009. 03376.x
28. Esposito I, Kleeff J, Bergmann F, Reiser C, Herpel E, Friess H, et al. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol. 2008; 15:1651–60. PMID: 18351300. doi: 10.1245/s10434-008-9839-8